Health Care Select Sector SPDR Fund (XLV)…

Home

Daily Stock Opinions and Ratings

Health Care Select Sector SPDR Fund (XLV)

171.45

-1.81 (1.04%)

as of Sep 4, 2026, 8:00:00 pm Market Open.

90 watching

Investor Insights

Sep 5, 2026, 12:00 am

This summary was created by AI, based on 5 opinions in the last 12 months.

The Health Care Select Sector SPDR Fund (XLV-N) has garnered positive reviews from various experts in the healthcare investment sector. Recent advancements in biotechnology, specifically relating to MRNA and MRK's combined therapies for melanoma, appear to be driving interest in the healthcare sector, suggesting a potential rotation away from technology investments. The fund has shown a significant outperformance compared to the S&P 500 over the past three months, highlighting its resilience and stability, particularly amid the current market dynamics. Additionally, the fund's low expense ratio and satisfactory dividend yield make it an attractive option for investors seeking steady growth. With a beta of 0.51, XLV is considered a safer and more reliable investment in an uncertain market, leading many to view it favorably for both short-term and long-term holdings.

Consensus

Buy

Valuation

Fair Value

Similar

JNJ

PAST TOP PICK

(A Top Pick May 05/21, Up 14%) Recently pulled up again, with defensive sectors doing quite well. He sold in October. Longer term, in 2022, healthcare will be a good sector to be in. Put it on the back burner for now, and take a look again in May.

BUY

Long-term, really likes the sector. When things are hot, the sector may lag. XLV has about 65 names. Aging demographics, growing emerging markets and middle class, increased healthcare spending. This year, healthcare ranks #8 out of 11 sectors. But if you're concerned about the long term, which he thinks you should be, XLV is a good place to start.

DON'T BUY

Better to buy the holdings? He doesn't buy ETFs, because he's an active manager. He'd rather buy the individual stocks, and he doesn't know what's in this ETF, though Thermo-Fisher, a key holding, is a fine company. In this sector, he owns Anthem, Abbvie and CVS, for example. Healthcare isn't in the sun now, but you can do well if you pick the right stocks.

TOP PICK

There's been talk of change of the US healthcare system for years, but Covid is making it difficult to do that right now and makes healthcare protected from attack. Strong seasonal period right now. Elective surgeries coming back. Huge opportunity for an uptick at least until August. Yield is 1.39%.

PAST TOP PICK

(A Top Pick May 07/20, Up 8%) Healthcare sector is a bit exhausted right now, and seeing relative weakness. He's walked back from it a bit. Coming up to an election, healthcare can become a political football.

TOP PICK

The healthcare sector has outperformed the S&P since February. There is a lot of money going into this sector. It tends to do well this time of year also. We also have to be more cautious in election years but it will be harder for this sector to be kicked back and forth like a football.

PAST TOP PICK

(A Top Pick May 09/19, Up 4%) Seasonality ends Oct. 24. It's been faltering lately. The US election campaign is a headwind and will continue to overhang. He may exit this.

PAST TOP PICK

(A Top Pick Sep 12/18, Down 1%) He was stopped out of this. The medical devices space is good. Biotech services, are under huge pressure. This ETF was a little too inclusive so he exited.

COMMENT

US Healthcare For knee replacements and implants he likes SNN-N. He does not prefer the ETFs, such as XLV-N, because they hold too broad of an array of companies, including the big drug companies that are under pressure. He would focus on the tool and device space instead.

PAST TOP PICK

(A Top Pick Aug 07/18, Up 1%) He was stopped out a while ago. Managed care got hit and became politicized. The sector went neutral, so he went into medical devices instead.

TOP PICK

It is defensive with a seasonal period from May first to the beginning of August. Investors get attracted to this sector at this time of the year because it is defensive. It has started to outperform the market. It is less exposed to the China/US trade deal. It is not a bad place to be. It is a place to hide out in.

TOP PICK

Buying beta. Can drop with the market but high quality market exposure. Tends to have high cash flow, large cap, robust companies, well diversified. Yield 1.6%.

TOP PICK

You want to focus your portfolio on leadership. He likes healthcare late cycle. These tend to have a higher cap. This is the largest diversified exposure in his portfolio.

TOP PICK

It's the largest by far in this space and cheap at 0.13% MER. Carries the biggies in healthcare with J&J, Pfizer as the top two holdings. It's highly liquid. He wants US dollars now, which is another plus. Also likes ZUB-T, but he prefers U.S. dollars.

TOP PICK

He feels the market is near the late stages of the bull run, but feels this balanced portfolio will continue to work well.

Showing 31 to 45 of 67 entries

Most Recent Experts

Kevin Simpson

Capital Wealth Planning

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Cerity Partners

Brian Madden

First Avenue Investment Counsel

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Health Care Select Sector SPDR Fund (XLV)